Company: PFSA
Filing Date: 2025-04-28
Form Type: S-4/A
Source: 0001213900-25-035718
Chunk: 472

Company: Profusa, Inc.
Filing Date: 2025-04-28
Form: S-4/A
Chunk 472
---
     |  (95 | )% |
| Total other expense, net                                                 |     |              | (4,730 | )    |     |   |  (4,211 | ) |     |        |   (519 | ) |     |   12 | %  |
| Net loss                                                                 |     | $            | (9,230 | )    |     | $ | (10,281 | ) |     | $      |  1,051 |   |     |  (10 | )% |

Revenue —Revenue increased from $0.05 to $0.1million from December31, 2023 to December31, 2024. Government grant revenue consists of amounts the Company earns under grants from two government agencies: NIH and DARPA. Refer to the “Government Grant Revenue” section in Note 2 of the notes to our audited consolidated financial statements included in this Report for more information. On March1, 2023, the Company was awarded a cost reimbursable subcontract by the Henry Jackson Foundation (“HJF”). HJF partnered with Profusa to deploy and evaluate a continuous wireless biosensing technology, the Lumee Oxygen Platform, with the Austere environments Consortium for Enhanced Sepsis Outcomes (“ACESO”). ACESO’s collaborator, the Komfo Anokye Teaching Hospital (“KATH”) in Kumasi, Ghana. The scope of this Statement of Work (SOW) encompasses Profusa’s activities to support the clinical study to be performed in Ghana under Protocol NMRC.2022.0001 to understand subdermal oxygenation during sepsis by enabling detection of tissue oxygen levels and fluctuations in core and peripheral body sites. The total amount of the subcontract to Profusa in 2024 was less than $0.01million. The sepsis clinical study subcontract is a cost reimbursable program that pays for all direct costs plus fringe at the DCAA approved billing rate of 24.69% and G&A at the DCAA approved billing rate of 45.66%. This increase in revenue was the result of the Company beginning work on the subcontract to evaluate a continuous wireless biosensing technology, the Lumee Oxygen product, and to provide clinical data in a sepsis clinical study. Research and Development— Research and development expenses decreased by $0.4 million, or 21%, to $1.6 million during the year ended December31, 2024 from $2.0 million during the year ended